RGNX

REGENXBIO Inc.

12.01 USD
-0.01 (-0.08%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

REGENXBIO Inc. stock is down -19.72% since 30 days ago. The next earnings date is Jul 31, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 8 June’s closed higher than May. 100% of analysts rate it a buy.

About REGENXBIO Inc.

REGENXBIO Inc. provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells to produce therapeutic proteins or antibodies that are intended to impact disease. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration.

  • HC Wainwright & Co.
    Thu Jun 20, 11:24
    buy
    confirm
  • Goldman Sachs
    Fri Jun 7, 07:27
    buy
    initial